論文・総説 - 原田　浩之

分割表示  499 件中 161 - 180 件目  ／  全件表示 >>

  1. Tsuchihashi H, Naruse T, Yanamoto S, Okuyama K, Furukawa K, Omori K, Umeda M. Selective inhibition of PI3K110α as a novel therapeutic strategy for cetuximab-resistant oral squamous cell carcinoma. Oncol Rep. 2020.09; 44 (3): 863-872. ( PubMed, DOI )

  2. Hirai H, Ohsako T, Kugimoto T, Tomioka H, Michi Y, Kayamori K, Yoda T, Miura M, Yoshimura R, Harada H. Comparison of 50- and 66-Gy total irradiation doses for postoperative cervical treatment of patients with oral squamous cell carcinoma Oral Oncol. 2020.08; 107 104708. ( PubMed, DOI )

  3. Asano T, Sano M, Takei J, Sayama Y, Kaneko MK, Kato Y. Epitope mapping of the anti-diacylglycerol kinase monoclonal antibody DhMab-4 for immunohistochemical analysis Monoclon Antib Immunodiagn Immunother. 2020.08; 39 (4): 117-122. ( PubMed, DOI )

  4. Shibata E, Morita KI, Kayamori K, Maruiwa M, Michi Y, Sato Y, Takeuchi K, Ikeda T, Harada H, Yoda T. Secretory carcinoma around Stensen's duct misdiagnosed as salivary duct cyst Int J Clin Exp Pathol. 2020.08; 13 (8): 2211-2217. ( PubMed )

  5. Kato Y, Ohishi T, Takei J, Nakamura T, Sano M, Asano T, Sayama Y, Hosono H, Kawada M, Kaneko MK. An Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody H 2 Mab-19 Exerts Antitumor Activity in Mouse Colon Cancer Xenografts Monoclon Antib Immunodiagn Immunother. 2020.08; 39 (4): 123-128. ( PubMed, DOI )

  6. Takei J, Ohishi T, Kaneko MK, Harada H, Kawada M, Kato Y. A defucosylated anti-PD-L1 monoclonal antibody 13-mG 2a-f exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma Biochem Biophys Rep. 2020.08; 30 (24): 100801. ( PubMed, DOI )

  7. Kaneko MK, Sano M, Takei J, Asano T, Sayama Y, Hosono H, Kobayashi A, Konnai S, Kato Y. Development and Characterization of Anti-Sheep Podoplanin Monoclonal Antibodies PMab-253 and PMab-260 Monoclon Antib Immunodiagn Immunother. 2020.08; 39 (4): 144-145. ( PubMed, DOI )

  8. Kato Y, Ohishi T, Takei J, Nakamura T, Kawada M, Kaneko MK. An Antihuman Epidermal Growth Factor Receptor 2 Monoclonal Antibody (H2Mab-19) Exerts Antitumor Activity in Glioblastoma Xenograft Models Monoclon Antib Immunodiagn Immunother. 2020.08; 39 (4): 135-139. ( PubMed, DOI )

  9. Kinoshita N, Sasaki Y, Marukawa E, Hirose R, Sawada SI, Harada H, Akiyoshi K. Crosslinked nanogel-based porous hydrogel as a functional scaffold for tongue muscle regeneration J Biomater Sci Polym Ed. 2020.07; 31 (10): 1254-1271. ( PubMed, DOI )

  10. Yamada SI, Hasegawa T, Okuyama K, Yamakawa N, Okura M, Hashidume M, Yanamoto S, Akashi M, Kirita T, Umeda M, Kurita H. Clinical significance of the G8 screening tool in elderly patients with oral squamous cell carcinoma Clin Oral Investig. 2020.06; 24 (6): 1953-1961. ( PubMed, DOI )

  11. Kato Y, Ohishi T, Sano M, Asano T, Sayama Y, Takei J, Kawada M, Kaneko MK. H2Mab-19 Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody Therapy Exerts Antitumor Activity in Pancreatic Cancer Xenograft Models Monoclon Antib Immunodiagn Immunother. 2020.06; 39 (3): 61-65. ( PubMed, DOI )

  12. Kato Y, Takei J, Sano M, Asano T, Sayama Y, Uchida K, Nakagawa T, Kaneko MK. Detection of lion podoplanin using the anti-tiger podoplanin monoclonal antibody PMab-231 Monoclon Antib Immunodiagn Immunother. 2020.06; 39 (3): 91-94. ( PubMed, DOI )

  13. Kato Y, Furusawa Y, Sano M, Takei J, Nakamura T, Yanaka M, Okamoto S, Handa S, Komatsu Y, Asano T, Sayama Y, Kaneko MK. Development of an Anti-Sheep Podoplanin Monoclonal Antibody PMab-256 for Immunohistochemical Analysis of Lymphatic Endothelial Cells Monoclon Antib Immunodiagn Immunother. 2020.06; 39 (3): 82-90. ( PubMed, DOI )

  14. Sayama Y, Sano M, Asano T, Furusawa Y, Takei J, Nakamura T, Yanaka M, Okamoto S, Handa S, Komatsu Y, Nakamura Y, Yanagawa M, Kaneko MK, Kato Y. Epitope mapping of PMab-241, a lymphatic endothelial cell-specific anti-bear podoplanin monoclonal antibody Monoclon Antib Immunodiagn Immunother. 2020.06; 39 (3): 77-81. ( PubMed, DOI )

  15. Takagawa Y , Gen Y, Muramatsu T, Tanimoto K, Inoue J, Harada H, Inazawa J . miR-1293, a Candidate for miRNA-Based Cancer Therapeutics, Simultaneously Targets BRD4 and the DNA Repair Pathway Mol ther. 2020.06; 28 (6): 1494-1505. ( PubMed, DOI )

  16. Uesugi A, Mochida K, Harada H, Imai H. Ossifying fibroma arising from the zygomatic arch: A case report. Journal of stomatology, oral and maxillofacial surgery. 2020.06; 121 (3): 288-291. ( PubMed, DOI )

  17. Kaneko A, Marukawa E, Harada H. Hydroxyapatite Nanoparticles as Injectable Bone Substitute Material in a Vertical Bone Augmentation Model In Vivo. 2020.05; 34 (3): 1053-1061.

  18. Kashima Y, Nishii N, Tachinami H, Furusawa E, Nagai S, Harada H, Azuma M. Orthotopic tongue squamous cell carcinoma (SCC) model exhibiting a different tumor-infiltrating T-cell status with margin-restricted CD8+ T cells and regulatory T cell-dominance, compared to skin SCC. Biochem Biophys Res Commun. 2020.05; 526 (1): 218-224. ( PubMed, DOI )

  19. Shimamoto H, Hirota Y, Kashima Y, Kinoshita N, Yokokawa M, Ikeda T, Harada H. Granulocyte colony-stimulating factor-producing squamous cell carcinoma of the tongue exhibiting characteristic fluorine-18 deoxyglucose accumulation on positron emission tomography–computed tomography: A case report World J Clin Case. 2020.05; 8 (9): 1666-1673. ( PubMed, DOI )

  20. Naruse T, Yanamoto S, Okuyama K, Ohmori K, Tsuchihashi H, Furukawa K, Yamada SI, Umeda M. Immunohistochemical Study of PD-1/PD-L1 Axis Expression in Oral Tongue Squamous Cell Carcinomas: Effect of Neoadjuvant Chemotherapy on Local Recurrence Pathol Oncol Res. 2020.04; 26 (2): 735-742. ( DOI )

< 前のページ - 次のページ >

このページの先頭へ▲